98%
921
2 minutes
20
COVID-19 can range from asymptomatic to life-threatening. Early identification of patients who will develop severe disease is crucial. A number of scores and indexes have been developed to predict severity. However, most rely on measurements not readily available. We evaluated hematological and biochemical markers taken on admission and determined how predictive they were of development of critical illness or death. We observed that higher values of readily available tests, including neutrophil:lymphocyte ratio; derived neutrophil index; and troponin I were associated with a higher risk of death or critical care admission (P < 0.001). We show that common hematological tests can be helpful in determining early in the course of illness which patients are likely to develop severe forms, as well as allocating resources to those patients early, while avoiding overuse of limited resources in patients with reduced risk of progression to severe disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860942 | PMC |
http://dx.doi.org/10.1016/j.clim.2021.108682 | DOI Listing |
FASEB J
September 2025
Department of Hematology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China.
Epilepsy is a common chronic nervous system disease that threatens human health. However, the role of FOXC1 and its relations with pyroptosis have not been fully studied in epilepsy. Sprague-Dawley rats were obtained for constructing temporal lobe epilepsy (TLE) models.
View Article and Find Full Text PDFInt J Cancer
September 2025
Laboratory for Computational Physiology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
The rise in cancer patients could lead to an increase in intensive care units (ICUs) admissions. We explored differences in treatment practices and outcomes of invasive therapies between patients with sepsis with and without cancer. Adults from 2008 to 2019 admitted to the ICU for sepsis were extracted from the databases MIMIC-IV and eICU-CRD.
View Article and Find Full Text PDFOrbit
September 2025
Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.
VEXAS syndrome is a rare disorder marked by systemic inflammation and blood disorders, caused by somatic mutations in the gene of hematopoietic stem cells. Ocular manifestations are common in VEXAS syndrome. This study reports a 63-year-old male presenting with recurrent periorbital and orbital inflammation, dacryoadenitis, and orbital myositis.
View Article and Find Full Text PDFEndocr Relat Cancer
September 2025
Endocrinology, Diabetology and Medical Andrology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
Bone metastases (BMs) are rare and late event in patients with neuroendocrine tumors (NETs). The aim of our study was to investigate clinical presentation and outcome of BMs in a large cohort of patients with NETs. A retrospective study was performed at two referral centers of Northern Italy (IRCCS Humanitas Research Hospital in Milan and S.
View Article and Find Full Text PDFBlood Neoplasia
November 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123 monocytes and plasmacytoid dendritic cells (pDCs). pDC bone marrow clusters in CMML have been associated with higher rates of acute myeloid leukemia transformation. We evaluated tagraxofusp, a CD123-targeted therapy, in a phase 1/2 trial for patients with CMML.
View Article and Find Full Text PDF